256 related articles for article (PubMed ID: 32414848)
1. Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia.
Loftus JP; Yahiaoui A; Brown PA; Niswander LM; Bagashev A; Wang M; Schauf A; Tannheimer S; Tasian SK
Haematologica; 2021 Apr; 106(4):1067-1078. PubMed ID: 32414848
[TBL] [Abstract][Full Text] [Related]
2. Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of
Walker AR; Byrd JC; Blachly JS; Bhatnagar B; Mims AS; Orwick S; Lin TL; Crosswell HE; Zhang D; Minden MD; Munugalavadla V; Long L; Liu J; Pan Y; Oellerich T; Serve H; Rao AV; Blum WG
Clin Cancer Res; 2020 Nov; 26(22):5852-5859. PubMed ID: 32820015
[TBL] [Abstract][Full Text] [Related]
3. Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia.
Urtishak KA; Wang LS; Culjkovic-Kraljacic B; Davenport JW; Porazzi P; Vincent TL; Teachey DT; Tasian SK; Moore JS; Seif AE; Jin S; Barrett JS; Robinson BW; Chen IL; Harvey RC; Carroll MP; Carroll AJ; Heerema NA; Devidas M; Dreyer ZE; Hilden JM; Hunger SP; Willman CL; Borden KLB; Felix CA
Oncogene; 2019 Mar; 38(13):2241-2262. PubMed ID: 30478448
[TBL] [Abstract][Full Text] [Related]
4. Multi-omics analysis defines highly refractory RAS burdened immature subgroup of infant acute lymphoblastic leukemia.
Isobe T; Takagi M; Sato-Otsubo A; Nishimura A; Nagae G; Yamagishi C; Tamura M; Tanaka Y; Asada S; Takeda R; Tsuchiya A; Wang X; Yoshida K; Nannya Y; Ueno H; Akazawa R; Kato I; Mikami T; Watanabe K; Sekiguchi M; Seki M; Kimura S; Hiwatari M; Kato M; Fukuda S; Tatsuno K; Tsutsumi S; Kanai A; Inaba T; Shiozawa Y; Shiraishi Y; Chiba K; Tanaka H; Kotecha RS; Cruickshank MN; Ishikawa F; Morio T; Eguchi M; Deguchi T; Kiyokawa N; Arakawa Y; Koh K; Aoki Y; Ishihara T; Tomizawa D; Miyamura T; Ishii E; Mizutani S; Wilson NK; Göttgens B; Miyano S; Kitamura T; Goyama S; Yokoyama A; Aburatani H; Ogawa S; Takita J
Nat Commun; 2022 Aug; 13(1):4501. PubMed ID: 36042201
[TBL] [Abstract][Full Text] [Related]
5. Genetic and Epigenetic Characterization of a Discordant
Russo A; Viberti C; Mareschi K; Casalone E; Guarrera S; Birolo G; Cazzaniga G; Corral L; Trentin L; Basso G; Fagioli F; Matullo G
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575904
[TBL] [Abstract][Full Text] [Related]
6. First report of t(5;11) KMT2A-MAML1 fusion in de novo infant acute lymphoblastic leukemia.
Tandon S; Shago M; Davidson S; Kanwar N; Fuligni F; Shlien A; Whitlock J; Villani A; Abla O
Cancer Genet; 2020 Oct; 248-249():31-33. PubMed ID: 32992102
[TBL] [Abstract][Full Text] [Related]
7. FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631.
Brown PA; Kairalla JA; Hilden JM; Dreyer ZE; Carroll AJ; Heerema NA; Wang C; Devidas M; Gore L; Salzer WL; Winick NJ; Carroll WL; Raetz EA; Borowitz MJ; Small D; Loh ML; Hunger SP
Leukemia; 2021 May; 35(5):1279-1290. PubMed ID: 33623141
[TBL] [Abstract][Full Text] [Related]
8. KMT2A (MLL) rearrangements observed in pediatric/young adult T-lymphoblastic leukemia/lymphoma: A 10-year review from a single cytogenetic laboratory.
Peterson JF; Baughn LB; Pearce KE; Williamson CM; Benevides Demasi JC; Olson RM; Goble TA; Meyer RG; Greipp PT; Ketterling RP
Genes Chromosomes Cancer; 2018 Nov; 57(11):541-546. PubMed ID: 30203571
[TBL] [Abstract][Full Text] [Related]
9. HMGA2 as a potential molecular target in KMT2A-AFF1-positive infant acute lymphoblastic leukaemia.
Wu Z; Eguchi-Ishimae M; Yagi C; Iwabuki H; Gao W; Tauchi H; Inukai T; Sugita K; Ishii E; Eguchi M
Br J Haematol; 2015 Dec; 171(5):818-29. PubMed ID: 26403224
[TBL] [Abstract][Full Text] [Related]
10. Amlexanox Downregulates S100A6 to Sensitize
Tamai H; Yamaguchi H; Miyake K; Takatori M; Kitano T; Yamanaka S; Yui S; Fukunaga K; Nakayama K; Inokuchi K
Cancer Res; 2017 Aug; 77(16):4426-4433. PubMed ID: 28646023
[TBL] [Abstract][Full Text] [Related]
11. The role of constitutive activation of FMS-related tyrosine kinase-3 and
Fedders H; Alsadeq A; Schmäh J; Vogiatzi F; Zimmermann M; Möricke A; Lenk L; Stadt UZ; Horstmann MA; Pieters R; Schrappe M; Stanulla M; Cario G; Schewe DM
Haematologica; 2017 Nov; 102(11):e438-e442. PubMed ID: 28838992
[No Abstract] [Full Text] [Related]
12. MLL-Rearranged Acute Lymphoblastic Leukemia.
El Chaer F; Keng M; Ballen KK
Curr Hematol Malig Rep; 2020 Apr; 15(2):83-89. PubMed ID: 32350732
[TBL] [Abstract][Full Text] [Related]
13. Cryptic recurrent ACIN1-NUTM1 fusions in non-KMT2A-rearranged infant acute lymphoblastic leukemia.
Pincez T; Landry JR; Roussy M; Jouan L; Bilodeau M; Laramée L; Couture F; Sinnett D; Gendron P; Hébert J; Oligny L; Rouette A; Tran TH; Wilhelm BT; Bittencourt H; Cellot S
Genes Chromosomes Cancer; 2020 Feb; 59(2):125-130. PubMed ID: 31515871
[TBL] [Abstract][Full Text] [Related]
14. De novo activating mutations drive clonal evolution and enhance clonal fitness in KMT2A-rearranged leukemia.
Hyrenius-Wittsten A; Pilheden M; Sturesson H; Hansson J; Walsh MP; Song G; Kazi JU; Liu J; Ramakrishan R; Garcia-Ruiz C; Nance S; Gupta P; Zhang J; Rönnstrand L; Hultquist A; Downing JR; Lindkvist-Petersson K; Paulsson K; Järås M; Gruber TA; Ma J; Hagström-Andersson AK
Nat Commun; 2018 May; 9(1):1770. PubMed ID: 29720585
[TBL] [Abstract][Full Text] [Related]
15. Azacitidine successfully maintained the second remission in an infant with KMT2A-rearranged acute lymphoblastic leukemia who relapsed after unrelated cord blood transplantation.
Chijimatsu I; Imanaka Y; Tomizawa D; Eguchi M; Nishimura S; Karakawa S; Miki M; Hamamoto K; Fujita N
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28675638
[TBL] [Abstract][Full Text] [Related]
16. SYK Targeting Represents a Potential Therapeutic Option for Relapsed Resistant Pediatric
Serafin V; Porcù E; Cortese G; Mariotto E; Veltri G; Bresolin S; Basso G; Accordi B
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817853
[TBL] [Abstract][Full Text] [Related]
17. MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations.
Kerstjens M; Driessen EM; Willekes M; Pinhanços SS; Schneider P; Pieters R; Stam RW
Oncotarget; 2017 Feb; 8(9):14835-14846. PubMed ID: 27588400
[TBL] [Abstract][Full Text] [Related]
18. KMT2A-MLLT1 and the Novel SEC16A-KMT2A in a Cryptic 3-Way Translocation t(9;11;19) Present in an Infant With Acute Lymphoblastic Leukemia.
de Matos RRC; Ferreira GM; Meyer C; Marschalek R; Larghero P; Ribeiro RC; Liehr T; Othman M; Bizarro MTSM; Sobral da Costa E; Land MGP; Abdelhay E; Binato R; Silva MLM
J Pediatr Hematol Oncol; 2022 Apr; 44(3):e719-e722. PubMed ID: 34966090
[TBL] [Abstract][Full Text] [Related]
19. Molecular characterization of KMT2A fusion partner genes in 13 cases of pediatric leukemia with complex or cryptic karyotypes.
Ney Garcia DR; de Souza MT; de Figueiredo AF; Othman MAK; Rittscher K; Abdelhay E; Capela de Matos RR; Meyer C; Marschalek R; Land MGP; Liehr T; Ribeiro RC; Silva MLM
Hematol Oncol; 2017 Dec; 35(4):760-768. PubMed ID: 27282883
[TBL] [Abstract][Full Text] [Related]
20. Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study.
Pieters R; De Lorenzo P; Ancliffe P; Aversa LA; Brethon B; Biondi A; Campbell M; Escherich G; Ferster A; Gardner RA; Kotecha RS; Lausen B; Li CK; Locatelli F; Attarbaschi A; Peters C; Rubnitz JE; Silverman LB; Stary J; Szczepanski T; Vora A; Schrappe M; Valsecchi MG
J Clin Oncol; 2019 Sep; 37(25):2246-2256. PubMed ID: 31283407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
